Novavax Global Commercial Operations and COVID-19 Vaccine Update

Consistent efficacy across phase 3 studies Study 302: UK Phase 31 (N=15,203) Study 301: PREVENT-192,3 (N=29,960) Overall Efficacy 89.7% "Matched"/ Prototype 96.4% Prototype Efficacy Efficacy Against Variants Efficacy Against Severe Disease 86.3% Alpha (B.1.1.7) NS (all 5 severe cases in placebo group) 90.4% 100% (Non-Vol/VoC) 93.6% Alpha (B.1.1.7) 92.6% All Vol/VoC 100% "High Risk" Populations 90.9% novavax 1. Dunkle et al., 2021. DOI: 10.1056/NEJMoa2116185. 2. Heath et al., NEJM, 2021. DOI: 10.1056/NEJMoa2107659. 3. Toback et al., The Lancet Res Med, 2021. DOI: 10.1016/S2213-2600(21)00409-4 91.0% © 2023 NOVAVAX. All rights reserved. 28

View entire presentation